Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

Absci — a company that uses synthetic biology and machine learning to help pharmaceutical companies rapidly identify new drugs — went public Thursday.

Why it matters: Discovering a new drug usually takes years of trial and error and huge amounts of investment. Also, more often than not, a candidate will never make it to market.

  • Approaches that mine the intersection of AI and biology should help accelerate that timeline.

Situational awareness: After opening yesterday morning at $16 per share, Absci's stock was up more than 30% by the end of trading.

How it works: Absci's chief innovation is its ability to use the tools of synthetic biology to generate the proteins needed for drug manufacture in specialized E. coli bacteria, rather than the mammalian cells lines that have traditionally been used by the pharma industry.

  • Absci, based in Vancouver, Washington, also uses deep learning tools to rapidly sift through potential protein sequences in computer models, rather than the lab, and identify the ones that could have the most clinical benefit and be the most efficient to manufacture for trials.

What they're saying: "The drug discovery and manufacturing process is completely disjointed, which is why it requires years to go from idea to drug in the clinic," says Sean McClain, Absci's CEO.

  • "We're collapsing that into a single stage in an integrated drug creation platform, taking it from years down to weeks or months."

Context: The intersection of AI and biology is one of the most exciting areas in science today, with major implications for medicine.

  • Also Thursday, the Google-owned AI company DeepMind released a database that used AI to predict the 3D-shape of more than 350,000 proteins, which should help accelerate disease detective work and drug discovery.

The bottom line: As Absci matures, says McClain, it aims to become the "Google index search of drug discovery and manufacture," bringing the speed of computer programming to the time-consuming art of biology.

Go deeper

Sep 9, 2021 - Health

Biogen says Aduhelm's launch has dragged

Biogen's Alzheimer's drug has not been prescribed widely yet. Photo: Adam Glanzman/Bloomberg via Getty Images

The uptake for Aduhelm, the controversially approved Alzheimer's drug, has been a lot slower than expected as the drug faces "near-term challenges," Biogen CEO Michel Vounatsos said at the Morgan Stanley health care conference Thursday.

Between the lines: Physicians want to see Aduhelm's clinical trial data, which has not been published in a medical journal yet, and they want to know how and if they'll be paid for administering the IV drug, which has a $56,000-per-year list price.

12 mins ago - Science

All-civilian Inspiration4 is back on Earth after flight to space

A side-by-side of the Inspiration4 crew and a shot of their capsule on the way back to Earth. Photo: SpaceX

The all-civilian Inspiration4 crew is back on Earth after their three-day mission in orbit.

The big picture: The launch and landing of this fully amateur, private space crew marks a changing of the guard from spaceflight being a largely government-led venture to being under the purview of private companies.

28 U.S. citizens depart Afghanistan on Qatar Airways flight

Passengers board a Qatar Airways aircraft bound to Qatar at the airport in Kabul on September 10, 2021. Photo: Aamir Qureshi/AFP via Getty Images

The State Department on Saturday confirmed that a Qatar Airways charter flight left Kabul on Friday with 28 U.S. citizens and seven lawful permanent residents on board.

The big picture: Friday's flight is the third such airlift by Qatar Airways since the Taliban takeover of Afghanistan, AP reports.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!